Cargando…

Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment

BACKGROUND: The p64MW HPC and p48MW HPC flow diverters have reduced thrombogenicity due to hydrophilic coating. The purpose of this study was to evaluate its safety and efficacy in Mongolian patients under single antiplatelet therapy (SAPT) with prasugrel. MATERIALS AND METHODS: We performed a retro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhogal, Pervinder, Petrov, Andrey, Rentsenkhu, Ganbaatar, Nota, Baatarjan, Ganzorig, Erdenebat, Regzengombo, Boldbat, Jagusch, Sara, Henkes, Elina, Henkes, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178779/
https://www.ncbi.nlm.nih.gov/pubmed/34233547
http://dx.doi.org/10.1177/15910199211029503
_version_ 1784723131025326080
author Bhogal, Pervinder
Petrov, Andrey
Rentsenkhu, Ganbaatar
Nota, Baatarjan
Ganzorig, Erdenebat
Regzengombo, Boldbat
Jagusch, Sara
Henkes, Elina
Henkes, Hans
author_facet Bhogal, Pervinder
Petrov, Andrey
Rentsenkhu, Ganbaatar
Nota, Baatarjan
Ganzorig, Erdenebat
Regzengombo, Boldbat
Jagusch, Sara
Henkes, Elina
Henkes, Hans
author_sort Bhogal, Pervinder
collection PubMed
description BACKGROUND: The p64MW HPC and p48MW HPC flow diverters have reduced thrombogenicity due to hydrophilic coating. The purpose of this study was to evaluate its safety and efficacy in Mongolian patients under single antiplatelet therapy (SAPT) with prasugrel. MATERIALS AND METHODS: We performed a retrospective review of patients enrolled into our prospectively maintained database to identify all patients treated with either the p48MW HPC or p64MW HPC under SAPT. We recorded baseline demographics, aneurysm size and location, procedural complications, angiographic and clinical results. RESULTS: 24 patients, (female = 21, 87.5%), age 48.2 ± 11.6 years (range 25–63) underwent treatment of 30 aneurysms with either p64MW HPC or p48MW HPC. All aneurysms were saccular with dome width 8.2 ± 6.5 (range 1.6–26.0 mm) and dome height 7.6 ± 6.7 (range 1.6–30.0 mm). None of the aneurysms were previously treated. The average PRU was 54.6 ± 31.2 (range 1–127) on pre-operative VerifyNow testing. Angiographic follow-up was available for 13 patients (17 aneurysms), 183 ± 36 days post-procedure, at which point 64.7% of aneurysms (n = 11/17) were completely occluded and 11.8% (n = 2/17) had only neck remnants resulting in 76.5% of aneurysms being adequately occluded A single intra-operative complication (4.2%) occurred however all patients were mRS ≤1 at last follow-up. There were two post-operative complications neither of which resulted in permanent neurological morbidity. There were no instances of post-operative aneurysmal rupture or delayed parenchymal haemorrhage. The overall mortality was 0%. CONCLUSION: The efficacy and safety of p64MW HPC coated devices under SAPT is similar to uncoated flow diverters that require DAPT.
format Online
Article
Text
id pubmed-9178779
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-91787792022-06-10 Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment Bhogal, Pervinder Petrov, Andrey Rentsenkhu, Ganbaatar Nota, Baatarjan Ganzorig, Erdenebat Regzengombo, Boldbat Jagusch, Sara Henkes, Elina Henkes, Hans Interv Neuroradiol New Devices and Technology BACKGROUND: The p64MW HPC and p48MW HPC flow diverters have reduced thrombogenicity due to hydrophilic coating. The purpose of this study was to evaluate its safety and efficacy in Mongolian patients under single antiplatelet therapy (SAPT) with prasugrel. MATERIALS AND METHODS: We performed a retrospective review of patients enrolled into our prospectively maintained database to identify all patients treated with either the p48MW HPC or p64MW HPC under SAPT. We recorded baseline demographics, aneurysm size and location, procedural complications, angiographic and clinical results. RESULTS: 24 patients, (female = 21, 87.5%), age 48.2 ± 11.6 years (range 25–63) underwent treatment of 30 aneurysms with either p64MW HPC or p48MW HPC. All aneurysms were saccular with dome width 8.2 ± 6.5 (range 1.6–26.0 mm) and dome height 7.6 ± 6.7 (range 1.6–30.0 mm). None of the aneurysms were previously treated. The average PRU was 54.6 ± 31.2 (range 1–127) on pre-operative VerifyNow testing. Angiographic follow-up was available for 13 patients (17 aneurysms), 183 ± 36 days post-procedure, at which point 64.7% of aneurysms (n = 11/17) were completely occluded and 11.8% (n = 2/17) had only neck remnants resulting in 76.5% of aneurysms being adequately occluded A single intra-operative complication (4.2%) occurred however all patients were mRS ≤1 at last follow-up. There were two post-operative complications neither of which resulted in permanent neurological morbidity. There were no instances of post-operative aneurysmal rupture or delayed parenchymal haemorrhage. The overall mortality was 0%. CONCLUSION: The efficacy and safety of p64MW HPC coated devices under SAPT is similar to uncoated flow diverters that require DAPT. SAGE Publications 2021-07-07 2022-06 /pmc/articles/PMC9178779/ /pubmed/34233547 http://dx.doi.org/10.1177/15910199211029503 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle New Devices and Technology
Bhogal, Pervinder
Petrov, Andrey
Rentsenkhu, Ganbaatar
Nota, Baatarjan
Ganzorig, Erdenebat
Regzengombo, Boldbat
Jagusch, Sara
Henkes, Elina
Henkes, Hans
Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment
title Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment
title_full Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment
title_fullStr Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment
title_full_unstemmed Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment
title_short Early clinical experience with the p48MW HPC and p64MW HPC flow diverters in the anterior circulation aneurysm using single anti-platelet treatment
title_sort early clinical experience with the p48mw hpc and p64mw hpc flow diverters in the anterior circulation aneurysm using single anti-platelet treatment
topic New Devices and Technology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178779/
https://www.ncbi.nlm.nih.gov/pubmed/34233547
http://dx.doi.org/10.1177/15910199211029503
work_keys_str_mv AT bhogalpervinder earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment
AT petrovandrey earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment
AT rentsenkhuganbaatar earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment
AT notabaatarjan earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment
AT ganzorigerdenebat earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment
AT regzengomboboldbat earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment
AT jaguschsara earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment
AT henkeselina earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment
AT henkeshans earlyclinicalexperiencewiththep48mwhpcandp64mwhpcflowdivertersintheanteriorcirculationaneurysmusingsingleantiplatelettreatment